Posts Tagged ‘IrsiCaixa’

Friday February 17th, 2017

A therapeutic HIV vaccine clinical trial induces viral control in 5 people without taking antiretroviral therapy

A therapeutic HIV vaccine clinical trial showed, for the first time, that in some cases the immune system of HIV infected people can be reeducated to control the virus for long periods without taking antiretroviral treatment. In particular, 5 out of 13 participants who stopped treatment (38.5%) have been controlling the virus for 5, 13, 17, 20 and 27 weeks, respectively. The study, still ongoing, is conducted in Barcelona and tests a vaccine developed by researchers at Oxford University in combination with a drug, romidepsin, able to awaken latent viruses in the body. The study is conducted by IrsiCaixa and the Fight AIDS Foundation and performed at the ospital Clínic de Barcelona-IDIBAPS, the Germans Trias i Pujol University Hospital (Barcelona) and the community center BCN Checkpoint. Read the rest of this entry »

Comments Closed
Thursday November 10th, 2016

Scientists from the European AIDS Vaccine Initiative (EAVI2020) meet in Barcelona to analyze the results of the first year of the consortium

Scientists from 22 institutions in Europe, Australia, Canada and the United States meet in Barcelona on November 10-11 to discuss the trajectory and progress of the European AIDS Vaccine Initiative (EAVI2020). This initiative, funded by the European Commission with 23 million euro, started a year ago to accelerate the development of an effective vaccine against HIV. The three Spanish centers participating in the consortium are the IrsiCaixa AIDS Research Institute, which organizes the meeting in Barcelona, the IDIBAPS and the Institute of Health Carlos III. The participation of IrsiCaixa and IDIBAPS is part of HIVACAT, the Catalan research project for an AIDS vaccine.

Read the rest of this entry »

Comments Closed
Tuesday January 12th, 2016

Aelix Therapeutics gets €11.5M for therapeutic HIV vaccine

Aelix Therapeutics, a drug development company created from the HIVACAT project and specialized in the discovery and development of immunotherapies against HIV infection, has completed a funding round of €11.5 M. Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a syndicate of new investors including Johnson & Johnson Innovation – JJDC Inc. (“JJDC”), and Caixa Capital Risc, the venture capital division of Spain’s leading financial group, ‘la Caixa’. Doctors Josep M. Gatell, head of the Infectious Diseases Department at Hospital Clínic and IDIBAPS, Bonaventura Clotet and Christian Brander, from the Institute for AIDS Research (IrsiCaixa), and Jordi Naval, are co-founders of the company and in charge of this project.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Monday November 02nd, 2015

IDIBAPS and IrsiCaixa participate in a 23 million euro project to develop HIV vaccine

IDIBAPS and the IrsiCaixa AIDS Research Institute participate in the European AIDS Vaccine Initiative (EAVI2020), a project to to accelerate the search for an effective HIV vaccine. This initiative, that is part of the European Comission framework programme for research and innovation (Horizon2020), brings together leading HIV researchers from public organisations and biotech companies from across Europe, Australia, Canada and the USA. IrsiCaixa and IDIBAPS are members of this consortium in which participate 22 institutions. Dr. Joan Joseph, researcher at the Infectious Diseases and AIDS IDIBAPS team led by Dr. Josep M. Gatell, will coordinate the project conducted at IDIBAPS over the next 5 years. At IrsiCaixa, an institute led by Dr. Bonaventura Clotet, this project will be coordinated by Dr. Christian Brander, head of the Host Cellullar and Genetic Immunity group and member of the consortium’s steering comitee. The other spanish participant in the consortium is the Instituto de Salud Carlos III.

Read the rest of this entry »

Comments Closed